GenoMed Seeks Volunteers for Possible HIV Treatment
ST. LOUIS, Jan. 15 /PRNewswire-FirstCall/ -- GenoMed, Inc. (OTC Bulletin Board: GMED) ("the Company" or "GenoMed"), a St. Louis, Missouri-based genomics company, announced today that it is seeking volunteers who are either HIV-positive already, or at risk for becoming infected with HIV, to test a new treatment in addition to their current anti- HIV treatment.
GenoMed has discovered that an extremely safe class of drugs called ACE inhibitors may be useful for many serious diseases, including prevention of infection with the HIV virus and AIDS. ACE stands for "angiotensin converting enzyme."
GenoMed found that patients with HIV and AIDS tend to have overactivity of their ACE enzyme. A logical approach is to inhibit ACE in the host.
The research supporting this new treatment approach was published in October, 2002 in Diabetes Technology and Therapeutics.
About GenoMed
GenoMed, Inc. is a medical genomics company whose mission is to improve patient outcomes by identifying the genes that cause disease.
To volunteer, please contact GenoMed's Chief Medical Officer, Dr. David Moskowitz, tel. 314-977-0110, fax 928-395-2580, email: dwmoskowitz@genomedics.com or visit GenoMed at www.genomedics.com.
SOURCE GenoMed, Inc.
CONTACT: Dr. David Moskowitz, Chief Medical Officer of GenoMed, Inc.,
+1-314-977-0110, or fax, +1-928-395-2580, or dwmoskowitz@genomedics.com/
Web site: genomedics.com
. |
